SS-31 dose range
The amounts people commonly use, from the low end to the high end, with syringe units, schedule and half-life. The 11 published studies are one click away.
Human trials Also called Elamipretide
What it was studied for
Mitochondria (the cell's energy makers). Human trials in heart failure and mitochondrial muscle disease.
Studied for: Heart, blood vessels and energyAging and longevity
Common use ranges
From user guides and clinic write-ups. No drug label exists, and no study has tested these amounts in people. Sources agree on once a day and on 5 to 10 mg as the common range, but there is no trial data at those doses.
- Half-life
- Not measured in any published study
- How it is taken
- Shot under the skin (subcutaneous)
- How long people use it
- Community use runs about 4 to 12 weeks. A common pattern is 12 weeks on, 4 weeks off. Another guide says 4 to 8 weeks. The approved drug is taken every day with no break.
- Mixing used for the units
- 50 mg vial + 1 mL water. 1 unit on a U-100 insulin syringe = 500 mcg.
Pick your vial size and how much water you add. The units below change to match.
50 mg vial + 1 mL water: 1 unit = 500 mcg
| Tier | Each dose | Syringe units50 mg vial + 1 mL water | How often | Schedule | Vial lastsat this tier |
|---|---|---|---|---|---|
| Starting [1] | 5 mg | 10 units 0.10 mL | once a day | 5 mg once a day. This is the low end of the common community range. One guide lists an even lower 0.5 to 5 mg a day. | 10 days |
| Typical [2] | 10 mg | 20 units 0.20 mL | once a day | 10 mg once a day, the top of the 5 to 10 mg community range. | 5 days |
| Higher [3] | 20 mg | 40 units 0.40 mL | once a day | Some cycling protocols go up to 10 to 20 mg once a day. | 2 days |
| Approved drug dose (Barth syndrome) [4] | 40 mg | 80 units 0.80 mL | once a day | 40 mg once a day under the skin, every day, for patients 30 kg and up. 20 mg a day with severe kidney problems. This is the prescription label for one rare disease, not a common-use dose. | 1 day |
Good to know
- Elamipretide is FDA approved as Forzinity only for Barth syndrome. Every other use is off label.
- Community doses are about one eighth to one quarter of the 40 mg label dose. One source says this is driven by cost, not by evidence.
- All sources agree on once a day, under the skin.
- Vials are sold as 10 mg and 50 mg powder.
Sources for these amounts
- Starting: Outliyr SS-31 report · Peptide Protocol Wiki, SS-31 dosing · The Dose Guide, SS-31
- Typical: Outliyr SS-31 report · Peptide Protocol Wiki, SS-31 dosing
- Higher: Outliyr SS-31 report
- Approved drug dose (Barth syndrome): Outliyr SS-31 report (summarizes the Forzinity label) · Peptide Protocol Wiki, SS-31 dosing (trial doses)
How long people use it: Outliyr SS-31 report · The Dose Guide, SS-31 · Peptide Protocol Wiki, SS-31 dosing
Half-life: Forzinity (elamipretide) FDA label on DailyMed, section 12.3
Take the SS-31 chart with you
Get a one-page printable chart for SS-31, with the syringe units for each vial and water mix. We can also email you when a new SS-31 study is published.
This page shows what labels, clinics and users report, and what studies gave. It is not medical advice and not a recommendation for anyone. Many of these compounds are not approved for human use. Check your own medicines and lab work with a licensed clinician before using anything.
See the science: 11 published studies
Amounts given to people in studies
How it was given: Under the skin (SC). Early studies used IV.
Trials ran from 4 weeks to more than 3 years.
Amounts given to animals in studies
Every study used for this page
Proof grade: Human trials. Tested in randomized human trials. Amounts are quoted as each study reported them. Where the abstract does not state an amount, the row says so.
| Study | Who was studied | Amount given, as reported | Route | How often | How long | What the authors reported |
|---|---|---|---|---|---|---|
| PMID 320680022020 | Human, HFrEF (n=71) | 4 mg or 40 mg (LOW human SC) | SC | once daily | 28 consecutive days | No change in LV end-systolic volume vs placebo; well tolerated |
| PMID 295002922018 | Human, primary mitochondrial myopathy (n=36) | 0.01, 0.1, 0.25 mg/kg/h for 2 hours, dose-escalating (LOWEST per-kg human) | IV infusion | once daily | 5 days of treatment | Highest dose 64.5 m vs 20.4 m placebo on 6MWT (p=0.053), dose-dependent trend |
| PMID 320966132020 | Human, primary mitochondrial myopathy, crossover (n=30) | 40 mg/day | SC | daily | 4 weeks (then 4-wk washout, crossover) | 6MWT +19.8 m (p=0.0833), less fatigue on symptom scales |
| PMID 372684352023 | Human, PMM, phase 3 (n=218; 109 vs 109) | 40 mg/d | SC | daily | 24 weeks | Missed primary endpoints (6MWT, PMMSA fatigue) |
| PMID 386021812024 | Human, Barth syndrome open-label ext (n=10 entered, 8 reached wk 168) | 40 mg SC daily | SC | daily | 168 weeks (after 28-wk RCT) | Sustained 6MWT improvement (+96.1 m cumulative at wk 168) |
| PMID 396058742025 | Human, dry AMD with geographic atrophy (n=176; 117 vs 59) | 40 mg daily | SC | daily | 48 weeks plus 4 wk follow-up | Primary endpoints missed, slowed ellipsoid-zone loss |
| PMID 362501632022 | Mouse, aged and diet models (n not recorded; wt not stated, ~0.025 kg assumed) | 3 mg/kg | SC | 5 days per week | 10 months (18 to 28 months of age) | Healthier aging phenotypes (PMC full text) |
| PMID 317479052019 | Mouse C57BL/6 male, 21-23 g (n not recorded) | 5 mg/kg | IP | once 30 min pre-surgery, then daily x3 | 3 days | Less LPS-induced mitochondrial and memory impairment. Authors say 5 mg/kg is the most effective repeated dose in mouse models |
| PMID 297140402018 | Pig, metabolic syndrome (n=6 per group; wt not stated) | 0.1 mg/kg | SC | daily, 5 days/week | 4 weeks | Preserved renal microvasculature |
| PMID 242883962014 | Rabbit and guinea pig, ischemia/reperfusion (wt not recorded) | 0.05 mg/kg/hr (as "Bendavia") | IV infusion | continuous | 1 to 3 hours of reperfusion | Cut infarct size about 50% |
| PMID 310057512019 | Mouse, irradiation (n and wt not in abstract) | 6 mg/kg | route not in abstract | not in abstract | not in abstract | Higher survival after lethal radiation |
How to read the study numbers
- One study, one group. Each figure is what one team chose for its own participants or animals.
- Route matters. An amount given into a vein (IV) is not the same as the same amount under the skin, in the nose or by mouth.
- Animals are not small people. An animal amount is shown as the study gave it. It is not a human amount.
- Short studies. Many studies ran days or weeks. They do not show what happens over longer use.
Common questions
What amounts of SS-31 were used in human studies?
In the studies listed here, people were given from 4 mg daily up to 40 mg daily. The amount used most often was 40 mg daily. These are what study teams chose for their participants under supervision.
Where do these SS-31 numbers come from?
From 11 published studies, each linked to its PubMed or ClinicalTrials.gov record. Every figure was checked against the study abstract or its open full text. Proof grade: Human trials.
How long does SS-31 stay in the body?
No published study has measured the half-life of SS-31, so nobody knows exactly how long one dose stays in the blood.
Is this a recommendation for how much SS-31 to use?
No. This page shows the amounts reported by drug labels, clinics and users, next to what researchers gave in studies. It is not medical advice and not a recommendation for anyone. Talk to a licensed clinician before using any of it.
Other peptides studied for heart, blood vessels and energy
See every peptide studied for heart, blood vessels and energy